biostudies-literatureKondili LAResearch Project PITER20101814-1825https://www.ebi.ac.uk/biostudies/studies/S-EPMC5765396biostudies-literatureUnknown66(6)We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus-infected patients: policy 1, "universal," treat all patients, regardless of fibrosis stage; policy 2, treat only "prioritized" patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus-infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were used to evaluate the policies' cost-effectiveness. The patients' age and fibrosis stage, assumed DAA treatment costHepatology (Baltimore, Md.)Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.PMC5765396RF-2010-2315839Russo FPFoti GKondili LACoppola CCiancio ARumi MGNardone GVinci MMontalto GFerrari CErne EMRuggeri MZuin MCraxi ASantantonio TAAndreone PPersico MRolli FRChemello LAlberti AVerucchi GMadonia SRomano FRosato STaliani GBorgia GPuoti MQuaranta MGDi Leo AMassari MBlanc PVella SZignego ALGasbarrini APITER Collaborating GroupChessa LCicchetti ARaimondo GVilla EIeluzzi DGaeta GBBrunetto MRfalseModeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus-infected patients: policy 1, "universal," treat all patients, regardless of fibrosis stage; policy 2, treat only "prioritized" patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus-infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were used to evaluate the policies' cost-effectiveness. The patients' age and fibrosis stage, assumed DAA treatment cost2017-01-01T00:00:00Z2017 Dec2025-04-04T11:30:39.855Z2019-03-27T00:14:54ZS-EPMC57653962874130710.1002/hep.29399